1Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Women’s Cancer Clinic, Yonsei University College of Medicine, Seoul, Korea
2Hereditary Cancer Clinic of Cancer Prevention Center, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
4Cancer Prevention Center, Yonsei Cancer Center, Seoul, Korea
5Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
6Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
Copyright © 2017 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | Overall population (n=116) | BRCA1/2 mutation (n=37) | BRCA1/2 VUS (n=25) | BRCA1/2 wild type (n=54) | p-value |
---|---|---|---|---|---|
Age | |||||
Mean±SD | 52.2±11.4 | 52.4±9.3 | 52.0±11.6 | 52.2±12.8 | 0.99a) |
Stage FIGO | |||||
I-II | 21 (18.1) | 2 (5.4) | 6 (24.0) | 13 (24.1) | 0.059b) |
III-IV | 94 (81.0) | 34 (91.9) | 19 (76.0) | 41 (75.9) | |
NI | 1 (0.9) | 1 (2.7) | 0 | 0 | |
Histology | |||||
Serous | 91 (78.4) | 32 (86.5) | 18 (72.0) | 41 (75.9) | 0.198b) |
Mucinous | 8 (6.9) | 0 | 2 (8.0) | 6 (11.1) | |
Endometrioid | 5 (4.3) | 0 | 2 (8.0) | 3 (5.6) | |
Clear cells | 5 (4.3) | 0 | 1 (4.0) | 4 (7.4) | |
Others | 3 (2.6) | 2 (5.4) | 1 (4.0) | 0 | |
NI | 4 (3.4) | 3 (8.1) | 1 (4.0) | 0 | |
Grade | |||||
02-1 | 45 (38.8) | 9 (24.3) | 10 (40.0) | 26 (48.1) | 0.260b) |
3 | 60 (51.7) | 23 (62.2) | 14 (56.0) | 23 (42.6) | |
NI | 11 (9.5) | 5 (13.5) | 1 (4.0) | 5 (9.3) | |
Optimal surgery | |||||
Yes | 82 (70.7) | 22 (59.5) | 20 (80.0) | 40 (74.1) | 0.130b) |
No | 22 (19.0) | 11 (29.7) | 0 | 11 (20.4) | |
NI | 12 (10.3) | 4 (10.8) | 5 (20.0) | 3 (5.6) | |
Personal history of breast cancer | |||||
Yes | 26 (22.4) | 18 (48.6) | 4 (16.0) | 4 (7.4) | < 0.001b) |
No | 89 (76.7) | 18 (48.6) | 21(84.0) | 50 (92.6) | |
NI | 1 (0.9) | 1 (2.7) | 0 | 0 | |
Family history of breast/ovarian cancer | |||||
Yes | 47 (40.5) | 18 (48.6) | 9 (36.0) | 20 (37.0) | 0.299b) |
No | 65 (56.0) | 16 (43.2) | 15 (60.0) | 34 (63.0) | |
NI | 4 (3.4) | 3 (8.1) | 1 (4.0) | 0 |
No. of patients | Complete and partial response | p-value | |
---|---|---|---|
BRCA1/2 mutation | 37 | 31 (83.8) | 0.898a) |
BRCA1/2 VUS | 25 | 22 (88.0) | |
BRCA1/2 wild type | 54 | 46 (85.2) |
Characteristic | Overall population (n=116) | BRCA1/2 mutation (n=37) | BRCA1/2 VUS (n=25) | BRCA1/2 wild type (n=54) | p-value |
---|---|---|---|---|---|
Age | |||||
Mean±SD | 52.2±11.4 | 52.4±9.3 | 52.0±11.6 | 52.2±12.8 | 0.99 |
Stage FIGO | |||||
I-II | 21 (18.1) | 2 (5.4) | 6 (24.0) | 13 (24.1) | 0.059 |
III-IV | 94 (81.0) | 34 (91.9) | 19 (76.0) | 41 (75.9) | |
NI | 1 (0.9) | 1 (2.7) | 0 | 0 | |
Histology | |||||
Serous | 91 (78.4) | 32 (86.5) | 18 (72.0) | 41 (75.9) | 0.198 |
Mucinous | 8 (6.9) | 0 | 2 (8.0) | 6 (11.1) | |
Endometrioid | 5 (4.3) | 0 | 2 (8.0) | 3 (5.6) | |
Clear cells | 5 (4.3) | 0 | 1 (4.0) | 4 (7.4) | |
Others | 3 (2.6) | 2 (5.4) | 1 (4.0) | 0 | |
NI | 4 (3.4) | 3 (8.1) | 1 (4.0) | 0 | |
Grade | |||||
02-1 | 45 (38.8) | 9 (24.3) | 10 (40.0) | 26 (48.1) | 0.260 |
3 | 60 (51.7) | 23 (62.2) | 14 (56.0) | 23 (42.6) | |
NI | 11 (9.5) | 5 (13.5) | 1 (4.0) | 5 (9.3) | |
Optimal surgery | |||||
Yes | 82 (70.7) | 22 (59.5) | 20 (80.0) | 40 (74.1) | 0.130 |
No | 22 (19.0) | 11 (29.7) | 0 | 11 (20.4) | |
NI | 12 (10.3) | 4 (10.8) | 5 (20.0) | 3 (5.6) | |
Personal history of breast cancer | |||||
Yes | 26 (22.4) | 18 (48.6) | 4 (16.0) | 4 (7.4) | < 0.001 |
No | 89 (76.7) | 18 (48.6) | 21(84.0) | 50 (92.6) | |
NI | 1 (0.9) | 1 (2.7) | 0 | 0 | |
Family history of breast/ovarian cancer | |||||
Yes | 47 (40.5) | 18 (48.6) | 9 (36.0) | 20 (37.0) | 0.299 |
No | 65 (56.0) | 16 (43.2) | 15 (60.0) | 34 (63.0) | |
NI | 4 (3.4) | 3 (8.1) | 1 (4.0) | 0 |
No. of patients | Complete and partial response | p-value | |
---|---|---|---|
BRCA1/2 mutation | 37 | 31 (83.8) | 0.898 |
BRCA1/2 VUS | 25 | 22 (88.0) | |
BRCA1/2 wild type | 54 | 46 (85.2) |
Gene | Site | Mutation | Mutation type | No. (%) (n=37) | BIC data |
---|---|---|---|---|---|
BRCA1 | Exon 11 | c.3627_3628insA (p.Leu1209_Glu1210?fs) | Frameshift | 5 (13.5) | Yes |
BRCA1 | Exon 7 | c.390C>A (p.Tyr130Ter) | Nonsense | 3 (8.1) | Yes |
BRCA1 | Exon 10 | c.1399A>T (p.Lys467Ter) | Nonsense | 2 (5.4) | Yes |
BRCA1 | Exon 11 | c.4041_4042delAG (p.Arg1347_Gly1348ArgAsnfs) | Frameshift | 2 (5.4) | Yes |
BRCA1 | Exon 11 | c.3442delG (p.Glu1148Argfs) | Frameshift | 2 (5.4) | Yes |
BRCA2 | Exon 15 | c.7480C>T(p.Arg2494Ter) | Nonsense | 2 (5.4) | Yes |
Gene | Site | Mutation | Mutation type | No. (%) (n=25) | BIC data |
---|---|---|---|---|---|
BRCA2 | Exon 18 | c.8187G>T (p.Lys2729Asn) | Missense | 4 (16.0) | Yes |
BRCA1 | Exon 16 | c.5339T>C(p.Leu1780Pro) | Missense | 3 (12.0) | Yes |
BRCA1 | Exon 16 | c.4883T>C (p.Met1628Thr) | Missense | 2 (8.0) | Yes |
Values are presented as number (%). VUS, variant of uncertain significance; SD, standard deviation; FIGO, International Federation of Gynecology and Obstetrics; NI, not indicated. ANOVA test, Chi-square Pearson’s test.
Values are presented as number (%). VUS, variant of uncertain significance. Chi-square Pearson’s test.
BIC, Breast Cancer Information Core.
VUS, variant of uncertain significance; BIC, Breast Cancer Information Core.